Notably, numerous compounds targeting IRE1 endonuclease domain (toyocamycin, STF-083010, 4μ8 C, MKC-3946, and B-I09) are currently evaluated in preclinical models of ER stress related disease, including cancer, with promising results3,39,1. Here, ERN1 is linked to cancer.